Platelet-rich plasma has beneficial effects in mice with osteonecrosis of the femoral head by promoting angiogenesis
- Shichao Tong
- Jimin Yin
- Ji Liu
Published online on: December 18, 2017
Copyright: © Tong et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Platelet-rich plasma (PRP) is autologous and multifunctional. Platelet concentrate from blood contains highly concentrated platelets and various types of cells, including growth factors. PRP promotes the recovery of cell proliferation and differentiation. Osteonecrosis of the femoral head is a disease caused by femoral head damage or an insufficient blood supply, which leads to the death of bone cells and abnormal bone marrow composition. The subsequent repair of bone cells may result in changes to the structure of femoral head, femoral head collapse and joint dysfunction. PRP may promote the repair of injured articular cartilage in patients with joint diseases through the removal of harmful inflammatory factors. In the present study, the therapeutic effects and primary mechanism of PRP action were investigated using a glucocorticoid‑induced femoral head osteonecrosis mouse model. Dexamethasone (DEX) and phosphate‑buffered saline were used as controls. The therapeutic efficacy of PRP to treat osteonecrosis in murine femoral heads was evaluated by assessing clinical arthritis scores. The present study indicated that mice with osteonecrosis of the femoral head treated with PRP exhibited downregulated expression of interleukin (IL)‑17A, IL‑1β, tumor necrosis factor‑α, receptor activator of nuclear factor κ‑B ligand, IL‑6 and interferon‑γ in the inflammatory tissue. In addition, the levels of hepatocyte growth factor, intercellular adhesion molecule‑1, osteopontin, platelet‑derived endothelial cell growth factor, vascular endothelial growth factor, platelet‑derived growth factor, insulin‑like growth factor‑1 and transforming growth factor‑β were increased following treatment with PRP. Joint tissue histological staining demonstrated that PRP alleviated osteonecrosis of the femoral head and reduced humoral and cellular immune responses that promoted beneficial effects on the histological parameters. Furthermore, the concentration of glucocorticoids were significantly decreased in the serum of PRP‑treated mice with osteonecrosis compared with the DEX group (P<0.01). Notably, PRP promoted beneficial effects in mice with osteonecrosis of the femoral head by stimulating angiogenesis. Therefore, the present study indicated that treatment with PRP promotes beneficial effects by preventing joint inflammation, cartilage destruction and bone damage, and stimulating the repair of joint tissue in mice with osteonecrosis of the femoral head. These preclinical data suggest that PRP may be developed as a novel method of treating osteonecrosis of the femoral head.